UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

Le traitement mensuel par palmitate de paliperidone (PP) versus les traitements antipsychotiques oraux journaliers retarde les conséquences négatives de la schizophrénie en « vie réelle » (étude PRIDE)

European psychiatry, 2014-11, Vol.29 (8), p.658-659

2014

Link zum Volltext

Verfügbarkeit prüfen

Étude comparant la subtitution de la rispéridone injectable à action prolongée par la palipéridone injectable à action prolongée versus une substitution par antipsychotiques oraux

European psychiatry, 2014-11, Vol.29 (8), p.658-658

2014

Link zum Volltext

Verfügbarkeit prüfen

An industry perspective on the NIMH consensus statement on negative symptoms

Schizophrenia bulletin, 2006-04, Vol.32 (2), p.225-230

Alphs, Larry

2006

Link zum Volltext

Verfügbarkeit prüfen

P.3.d.075 Once-monthly paliperidone palmitate compared with oral conventional or oral atypical antipsychotic treatment in patients with schizophrenia

European neuropsychopharmacology, 2015-09, Vol.25, p.S524-S525

2015

Link zum Volltext

Verfügbarkeit prüfen

P.1.k.032 The Suicide Ideation and Behavior Assessment Tool: development of a novel measure of suicidal ideation and behavior and perceived risk of suicide

European neuropsychopharmacology, 2015-09, Vol.25, p.S371-S371

2015

Link zum Volltext

Verfügbarkeit prüfen

P.3.d.048 Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia

European neuropsychopharmacology, 2014-10, Vol.24, p.S550-S551

2014

Link zum Volltext

Verfügbarkeit prüfen

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

Current medical research and opinion, 2010-02, Vol.26 (2), p.377-387

2010

Link zum Volltext

Verfügbarkeit prüfen

Health resource and Criminal Justice system costs for Young Clinical Trial Patients with Schizophrenia and prior Incareration by treatment failure status

Value in health, 2015-05, Vol.18 (3), p.A122-A122

2015

Link zum Volltext

Verfügbarkeit prüfen

Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms

Schizophrenia research, 2009-08, Vol.113 (1), p.56-64

2009

Link zum Volltext

Verfügbarkeit prüfen

P.3.d.023 Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder

European neuropsychopharmacology, 2014-10, Vol.24, p.S534-S535

2014

Link zum Volltext

Verfügbarkeit prüfen

P.3.b.018 Posthoc analysis of patient relapse rates when switching from risperidone or other antipsychotics to paliperidone palmitate

European neuropsychopharmacology, 2014-10, Vol.24, p.S501-S502

2014

Link zum Volltext

Verfügbarkeit prüfen

The Health-Related Quality of Life, Work Productivity, Healthcare Resource Utilization, and Economic Burden Associated with Levels of Suicidal Ideation Among Patients Self-Reporting Moderately Severe or Severe Major Depressive Disorder in a National Survey

Neuropsychiatric disease and treatment, 2021-01, Vol.17, p.111-123

2021

Link zum Volltext

Verfügbarkeit prüfen

The schedule for the deficit syndrome: An instrument for research in schizophrenia

Psychiatry research, 1989-11, Vol.30 (2), p.119-123

1989

Link zum Volltext

Verfügbarkeit prüfen

P.3.c.061 Paliperidone palmitate response in acutely ill patients with schizophrenia previously treated with oral risperidone

European neuropsychopharmacology, 2010, Vol.20, p.S493-S493

2010

Link zum Volltext

Verfügbarkeit prüfen

20 – Placebo response in controlled clinical trials of patients with schizophrenia: A decade of differences

Schizophrenia research, 2008-02, Vol.98, p.41-41

2008

Link zum Volltext

Verfügbarkeit prüfen

11 – Use of the 4-item Negative Symptom Assessment (NSA-4) by minimally trained clinicians

Schizophrenia research, 2008-02, Vol.98, p.37-37

2008

Link zum Volltext

Verfügbarkeit prüfen

301 – Patterns of response with paliperidone ER and placebo in patients with schizophrenia

Schizophrenia research, 2008-02, Vol.98, p.157-157

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia

Journal of clinical psychopharmacology, 2010-04, Vol.30 (2), p.106-115

2010

Link zum Volltext

Verfügbarkeit prüfen

P03-340 - A pooled analysis of the effects of asenapine on the persistent negative symptoms of schizophrenia

European psychiatry, 2011, Vol.26, p.1510-1510

2011

Link zum Volltext

Verfügbarkeit prüfen

P01-69 - Long-term asenapine treatment for bipolar disorder: a double-blind 40-week extension study

European psychiatry, 2010, Vol.25 (S1), p.290-290, Article 25-E288

2010

Link zum Volltext

Verfügbarkeit prüfen

Transcultural differences in suicide attempters: Analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder

Schizophrenia research, 2007-01, Vol.89 (1), p.140-146

2007

Link zum Volltext

Verfügbarkeit prüfen

Frequently relapsing bipolar disorder: Evidence for an effective treatment

Schizophrenia research, 2008-02, Vol.98, p.5-5

2008

Link zum Volltext

Verfügbarkeit prüfen

Randomized and placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorder

Schizophrenia research, 2008-02, Vol.98, p.5-6

2008

Link zum Volltext

Verfügbarkeit prüfen

48 – Psychometric evaluation of the Negative Symptom Assessment (NSA-16) scale in schizophrenic patients with predominant negative symptoms

Schizophrenia research, 2008-02, Vol.98, p.53-53

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(115)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Psychiatry
(71)
Science & Technology
(66)
Life Sciences & Biomedicine
(65)
Humans
(57)
Biological And Medical Sciences
(37)
Medical Sciences
(37)
Male
(34)
Adult
(31)
Psychology. Psychoanalysis. Psychiatry
(31)
Schizophrenia
(28)
Schizophrenia - Drug Therapy
(28)
Schizophrenic Psychology
(28)
Psychopathology. Psychiatry
(24)
Female
(23)
Pharmacology & Pharmacy
(20)
Adult And Adolescent Clinical Studies
(18)
Pharmacology. Drug Treatments
(18)
Antipsychotic Agents - Therapeutic Use
(17)
Middle Aged
(17)
Neurosciences & Neurology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Le traitement mensuel par palmitate de paliperidone (PP) versus les traitements antipsychotiques oraux journaliers retarde les conséquences négatives de la schizophrénie en « vie réelle » (étude PRIDE)

Étude comparant la subtitution de la rispéridone injectable à action prolongée par la palipéridone injectable à action prolongée versus une substitution par antipsychotiques oraux

An industry perspective on the NIMH consensus statement on negative symptoms

P.3.d.075 Once-monthly paliperidone palmitate compared with oral conventional or oral atypical antipsychotic treatment in patients with schizophrenia

P.1.k.032 The Suicide Ideation and Behavior Assessment Tool: development of a novel measure of suicidal ideation and behavior and perceived risk of suicide

P.3.d.048 Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

Health resource and Criminal Justice system costs for Young Clinical Trial Patients with Schizophrenia and prior Incareration by treatment failure status

Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms

P.3.d.023 Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder

P.3.b.018 Posthoc analysis of patient relapse rates when switching from risperidone or other antipsychotics to paliperidone palmitate

The Health-Related Quality of Life, Work Productivity, Healthcare Resource Utilization, and Economic Burden Associated with Levels of Suicidal Ideation Among Patients Self-Reporting Moderately Severe or Severe Major Depressive Disorder in a National Survey

The schedule for the deficit syndrome: An instrument for research in schizophrenia

P.3.c.061 Paliperidone palmitate response in acutely ill patients with schizophrenia previously treated with oral risperidone

20 – Placebo response in controlled clinical trials of patients with schizophrenia: A decade of differences

11 – Use of the 4-item Negative Symptom Assessment (NSA-4) by minimally trained clinicians

301 – Patterns of response with paliperidone ER and placebo in patients with schizophrenia

Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia

P03-340 - A pooled analysis of the effects of asenapine on the persistent negative symptoms of schizophrenia

P01-69 - Long-term asenapine treatment for bipolar disorder: a double-blind 40-week extension study

Transcultural differences in suicide attempters: Analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder

Frequently relapsing bipolar disorder: Evidence for an effective treatment

Randomized and placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorder

48 – Psychometric evaluation of the Negative Symptom Assessment (NSA-16) scale in schizophrenic patients with predominant negative symptoms

Suchergebnisse filtern